Azilsartan Medoxomil
Azilsartan medoxomil is an angiotensin II receptor blocker, commonly shortened to ARB, used for high blood pressure. MedicForce attaches one single-ingredient record and one fixed combination: Edarbi contains azilsartan medoxomil, while Edarbyclor also contains chlorthalidone.
Edarbyclor
Hypertension
40mg + 12.5mg
Indicated to address severe hypertension to relieve arterial tension and manage systemic fluid balance.
Key points
- Azilsartan blocks angiotensin II effects that would otherwise tighten blood vessels.
- Edarbi is represented as a single-ingredient 40 mg tablet.
- Edarbyclor pairs azilsartan medoxomil with chlorthalidone.
- Azilsartan-containing medicines carry a serious pregnancy warning.
The active form behind the two names
Azilsartan medoxomil is taken by mouth as a tablet. Blocking angiotensin II receptors allows blood vessels to remain more relaxed, which explains its role in hypertension and its place in the heart and blood pressure category.
The full name matters: catalogue and label sources use azilsartan medoxomil for the medicine ingredient, while patient information may shorten the discussion to azilsartan.
Edarbi and the chlorthalidone combination
Edarbi is the standalone ingredient record and lists a 40 mg tablet. Edarbyclor is a two-part formulation with a catalogue strength line of 40 mg plus 12.5 mg. The second ingredient is chlorthalidone, a diuretic, so Edarbyclor should be read as a complete combination identity.
Azilsartan can harm a developing fetus. Pregnancy status and any change involving this medicine require prompt, person-specific clinical direction.